Journal of Research in Medical Sciences

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 24  |  Issue : 1  |  Page : 30-

Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study


Hosein Kamranzadeh1, Reza Manouchehri Ardekani1, Amir Kasaeian1, Sanambar Sadighi2, Somaye Maghsudi1, Issa Jahanzad3, Nasrollah Maleki1 
1 Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Medical Oncology, Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Pathology, Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

Correspondence Address:
Dr. Reza Manouchehri Ardekani
Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Kargar Shomali Street, Tehran University of Medical Sciences, Tehran
Iran

Background: Breast cancer is the most common diagnosed female cancer. Breast cancer is also the leading cause of cancer death in females accounting for 13.7% of female cancer-related mortality globally. Variable known prognostic factors such as histological tumor type, tumor size, nodal status, grade, age, and estrogen receptor (ER) status and the proliferation marker – Ki-67 influence the type of treatment decision. The purpose of this present study is to investigate the association between Ki-67 expression with several clinicopathological variables and patients' outcome. Materials and Methods: This is a retrospective cohort study from September 2008 to March 2017; 165 newly diagnosed breast cancer patients were enrolled in the study. Ki67 levels were measured using immunohistochemistry and compared with clinicopathological variables. The relation of Ki67 expression with disease-free survival (DFS) and overall survival (OS) was also analyzed. Results: The result of this study revealed that age, tumor size, menopausal status, and human epidermal growth factor receptor 2 (HER2) status had no effect on the patients' outcome. Patients with ER-positive, progesterone receptor (PR)-positive, and HER2-negative tumors expressed a higher rate of Ki-67 (>10%) than patients with ER-negative, PR-negative, and HER2-positive tumors, respectively. However, we found that Ki-67 levels were not significantly increased statistically with ER, PR, and HER2 statuses. There was a statistically significant correlation between Ki-67 expression and with higher stages of the disease. Multivariate analysis showed that Ki-67 expression could not to be an independent prognostic factor for 5-year OS and DFS. Furthermore, p53 status was only prognostic factor for 5-year OS whereas higher stages of disease and p53 status were prognostic factors for 5-year DFS. Conclusion: Ki67 could not be an independent variable for prediction of breast cancer outcome.


How to cite this article:
Kamranzadeh H, Ardekani RM, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, Maleki N. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study.J Res Med Sci 2019;24:30-30


How to cite this URL:
Kamranzadeh H, Ardekani RM, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, Maleki N. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study. J Res Med Sci [serial online] 2019 [cited 2020 Feb 28 ];24:30-30
Available from: http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2019;volume=24;issue=1;spage=30;epage=30;aulast=Kamranzadeh;type=0